摘要
目的对恶性肿瘤伴发的泛发性带状疱疹的治疗进行探讨，并与恶性肿瘤伴发的局限于单侧的带状疱疹进行统计学分析。方法回顾分析我院自2000年1月至2011年7月住院期间共收治9例泛发性带状疱疹病人，同期收治恶性肿瘤伴发局限性带状疱疹28例，并对其进行统计学分析。结果恶性肿瘤伴发泛发性带状疱疹患者CD4／CD8降低比例为44．44％（4／9），恶性肿瘤伴有单纯性带状疱疹患者CD4／CD8降低比例为10．71％（3／28X二者比较有统计学意义（P〈0．05）。恶性肿瘤伴发泛发性带状疱疹患者结痂时间平均为（7．44±1．92）天，恶性肿瘤伴发单纯性带状疱疹患者结痂时间平均为（3．89±0．598）天，二者比较有显著统计学差异（P〈0．01）。结论恶性肿瘤伴发泛发性带状疱疹患者免疫功能低于恶性肿瘤伴发单纯性带状疱疹患者，且治疗后结痂时间长于后者。
Objective To explore the treatment for malignant tumors complicated with dis- seminated herpes zoster, and then compare with malignant tumors complicated with unilateral herpes zoster. Methods The data on 9 patients with malignant tumors and complicated with disseminated herpes zoster who had been treated from January 2000 to July 2011 were retrospectively analyzed, and so were the data on the 28 patients complicated with unilateral herpes zoster herpes zoster who had been treated during the same time. Results There was a significant difference in the CD4/CDs rate between the patients with disseminated herpes zoster and those with unilateral herpes zoster （ 44.44% vs. 10. 71% or 4/9 vs. 3/28, P 〈 0.05 ）. Time to scar formation differed significantly between the patients with disseminated herpes and those with unilateral herpes zoster（ [7.44 ＋ 1.926]d vs. [3.89：1： 0.598]d, P〈 0.01 ）. Conclusions The immune function is weaker in malignant tumor patients complicated with disseminated herpes zoster than in those with local herpes zoster. Time to scar formation is also longer in the patients with disseminated herpes zoster.
出处
《国际医药卫生导报》
2012年第5期620-623,共4页
International Medicine and Health Guidance News
关键词
恶性肿瘤
泛发性带状疱疹
治疗
Malignant tumors
Disseminated Herpes zoster
Treatment
